Quality Review
Meet the Q&PS Team
MedicASK Answers
MedicASK Answers Full List
Patient Safety Incident Report
Loss or theft of controlled substances
MedicASK
Files
Methoxyflurane in Head Injured Patients
Question# 989
Use of Methoxy and Head traumas. If a risk of administering Methoxy is lightheaded, sleepiness and dizziness, are there to be concerns/weariness about those with pt's with potential head trauma?
Answer:
Methoxyflurane is associated with central nervous system (CNS) effects such as lightheadedness, dizziness, drowsiness, and mild sedation. In patients with suspected head injury, these effects are clinically relevant because they may confound neurological assessment by mimicking or masking symptoms of intracranial injury. For this reason, methoxyflurane should be used cautiously where frequent and reliable neurological reassessment is required, and it should be avoided in patients with any reduced level of consciousness where changes in mental status must be closely monitored.
The Medical Directive reflects these concerns by requiring that patients receiving methoxyflurane be unaffected by altered level of consciousness and able to cooperate with self-administration. Because methoxyflurane is delivered via patient-controlled inhalation, patients must be able to understand instructions, maintain their airway, and actively inhale through the device. As such, methoxyflurane is contraindicated in patients with reduced consciousness due to head injury, alcohol, drugs, or any other cause, both for safety reasons and to ensure accurate neurological assessment.
Importantly, the patient-controlled/self-administered nature of methoxyflurane is itself an important safety feature. In patients with minor head injury who are fully conscious, cooperative, and neurologically intact, methoxyflurane may be considered with caution, provided a clear baseline neurological assessment is documented and frequent reassessment is performed, and provided the medication remains exclusively self-administered by the patient. If a patient begins to deteriorate neurologically, they will generally no longer be able to continue effective inhalation and will drop the device, immediately stopping further medication delivery. Given methoxyflurane’s rapid offset, this should minimize ongoing interference with reassessment.
It is important to reinforce that nobody other than the patient should ever hold the inhaler device during administration, including family members or providers attempting to assist. Similar issues were historically encountered with inhaled nitrous oxide, where bypassing the patient-controlled mechanism undermined an important safety safeguard.
Importantly, a risk-benefit approach is required, as CNS effects are not unique to methoxyflurane. Opioids, ketamine, and benzodiazepines, all medications carried by paramedics, also produce sedation, altered mentation, and potential interference with neurological assessment. The presence of a potential head injury does not automatically preclude analgesia; rather, clinicians must weigh the benefit of pain control against the risk of obscuring neurological changes, regardless of the agent chosen. If there is concern that any analgesic’s CNS effects may interfere with monitoring, alternative strategies or delayed escalation may be more appropriate.
To summarize, methoxyflurane does not worsen head injury, but its CNS effects, like those of opioids and other analgesics, can interfere with neurological assessment. For this reason, patients must be unaltered, cooperative, and able to self-administer, and clinicians must apply a risk-benefit approach when selecting analgesia in patients with suspected head trauma.
The Medical Directive reflects these concerns by requiring that patients receiving methoxyflurane be unaffected by altered level of consciousness and able to cooperate with self-administration. Because methoxyflurane is delivered via patient-controlled inhalation, patients must be able to understand instructions, maintain their airway, and actively inhale through the device. As such, methoxyflurane is contraindicated in patients with reduced consciousness due to head injury, alcohol, drugs, or any other cause, both for safety reasons and to ensure accurate neurological assessment.
Importantly, the patient-controlled/self-administered nature of methoxyflurane is itself an important safety feature. In patients with minor head injury who are fully conscious, cooperative, and neurologically intact, methoxyflurane may be considered with caution, provided a clear baseline neurological assessment is documented and frequent reassessment is performed, and provided the medication remains exclusively self-administered by the patient. If a patient begins to deteriorate neurologically, they will generally no longer be able to continue effective inhalation and will drop the device, immediately stopping further medication delivery. Given methoxyflurane’s rapid offset, this should minimize ongoing interference with reassessment.
It is important to reinforce that nobody other than the patient should ever hold the inhaler device during administration, including family members or providers attempting to assist. Similar issues were historically encountered with inhaled nitrous oxide, where bypassing the patient-controlled mechanism undermined an important safety safeguard.
Importantly, a risk-benefit approach is required, as CNS effects are not unique to methoxyflurane. Opioids, ketamine, and benzodiazepines, all medications carried by paramedics, also produce sedation, altered mentation, and potential interference with neurological assessment. The presence of a potential head injury does not automatically preclude analgesia; rather, clinicians must weigh the benefit of pain control against the risk of obscuring neurological changes, regardless of the agent chosen. If there is concern that any analgesic’s CNS effects may interfere with monitoring, alternative strategies or delayed escalation may be more appropriate.
To summarize, methoxyflurane does not worsen head injury, but its CNS effects, like those of opioids and other analgesics, can interfere with neurological assessment. For this reason, patients must be unaltered, cooperative, and able to self-administer, and clinicians must apply a risk-benefit approach when selecting analgesia in patients with suspected head trauma.